No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: A randomized controlled trial

Clinical Endocrinology

Volumn 70, Issue 4, 2009, Pages 522-526

  Anastasilakis, Athanasios D ^a,d   Goulis, Dimirtios G ^b   Polyzos, Stergios A ^a   Gerou, Spiridon ^c   Ballaouri, Iris ^c   Efstathiadou, Zoe ^a   Kita, Marina ^a   Avramidis, Avraam ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c 'Analysis' Laboratories   (Greece)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PARATHYROID HORMONE[1-34]; STRONTIUM RANELATE; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; OPEN STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; TERIPARATIDE; THIOPHENES; TREATMENT OUTCOME; VITAMIN D;

EID: 61449099574     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03342.x     Document Type: Article

References (29)

1. Ravn, P., Clemmesen, B. Christiansen, C. (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone, 24, 237 244.
2. Sarkar, S., Reginster, J., Crans, G. et al. (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. Journal of Bone and Mineral Research, 19, 394 401.
3. Eastell, R., Barton, I., Hannon, R. et al. (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of Bone and Mineral Research, 18, 1051 1056.
4. Chen, P., Satterwhite, J., Licata, A. et al. (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research, 20, 962 970.
5. Eastell, R., Krege, J., Chen, P. et al. (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Current Medical Research and Opinion, 22, 61 66.
6. Nenonen, A., Cheng, S., Ivaska, K. et al. (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. Journal of Bone and Mineral Research, 20, 1804 1812.
7. Rosen, H., Moses, A., Garber, J. et al. (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcified Tissue International, 66, 100 103.
8. Hodsman, A., Bauer, D., Dempster, D. et al. (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine Reviews, 26, 688 703.
9. Body, J., Gaich, G., Scheele, W. et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide recombinant human parathyroid hormone (1-34) with alendronate in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism, 87, 4528 4535.
10. Meunier, P., Roux, C., Seeman, E. et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine, 350, 459 468.
11. Reginster, J., Seeman, E., De Vernejoul, M. et al. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. Journal of Clinical Endocrinology and Metabolism, 90, 2816 2822.
12. Blake, G. Fogelman, I. (2007) The correction of BMD measurements for bone strontium content. Journal of Clinical Densitometry, 10, 259 265.
13. Ammann, P., Badoud, I., Barraud, S. et al. (2007) Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. Journal of Bone and Mineral Research, 22, 1419 1425.
14. Canalis, E., Hott, M., Deloffre, P. et al. (1996) The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone, 18, 517 523.
15. Marie, P. (2006) Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone, 38 (Suppl. 1 S10 S14.
16. Buehler, J., Chappuis, P., Saffar, J. et al. (2001) Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone, 29, 176 179.
17. Canalis, E., Giustina, A. Bilezikian, J. (2007) Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine, 357, 905 916.
18. Meunier, P., Slosman, D., Delmas, P. et al. (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. Journal of Clinical Endocrinology and Metabolism, 87, 2060 2066.
19. Rittmaster, R., Bolognese, M., Ettinger, M. et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. Journal of Clinical Endocrinology and Metabolism, 85, 2129 2134.
20. Holick, M. (2007) Vitamin D deficiency. New England Journal of Medicine, 357, 266 281.
21. Harris, S. (2006) Vitamin D and African Americans. Journal of Nutrition, 136, 1126 1129.
22. Binkley, N., Krueger, D., Cowgill, C. et al. (2004) Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. Journal of Clinical Endocrinology and Metabolism, 89, 3152 3157.
23. Neer, R., Arnaud, C., Zanchetta, J. et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344, 1434 1441.
24. Anastasilakis, A., Goulis, D., Polyzos, S. et al. (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized controlled trial. Hormone and Metabolic Research, 40, 281 285.
25. Delmas, P. (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporosis International, 11 (Suppl. 6 S66 S76.
26. Black, D., Bilezikian, J., Ensrud, K. et al. (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New England Journal of Medicine, 353, 555 565.
27. Chattopadhyay, N., Yano, S., Tfelt-Hansen, J. et al. (2004) Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology, 145, 3451 3462.
28. Bonnelye, E., Chabadel, A., Saltel, F. et al. (2008) Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone, 42, 129 138.
29. Brennan, T., Rybchyn, M., Conigrave, A. et al. (2006) Strontium ranelate effect on proliferation and OPG expression in osteoblasts. Calcified Tissue International, 78 (Suppl. 1 S129.